You just read:

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

09 Sep, 2016, 07:00 ET